This round takes place at the Business Technology Center, which is run by the Community Development Commission of the County of Los Angeles. The companies will then travel to the Bay Area to participate in the Innovation Shootout on January 15th at the Quadras Conference Center in Menlo Park. The winner will be selected by a panel of judges including technology experts, members of the media, and venture capitalists.ImpediMed's devices use bioimpedance spectroscopy (BIS) technologies in the noninvasive clinical assessment and monitoring of human disorders and diseases. Its primary product range consists of a number of medical devices that aid surgeons, oncologists, radiation oncologists, and therapists to clinically assess secondary unilateral lymphedema. Preoperative assessment in combination with periodic surveillance can assist medical professionals to detect lymphedema before the onset of visible symptoms and potentially before the condition progresses to irreversible forms. Irreversible lymphedema can become a lifelong management issue for patients and can significantly impair their quality of life."The increasing mantra from U.S. experts in the area of managing breast cancer patients is the recognition that preoperative assessment, early detection, and treatment of lymphedema is the best way to prevent and manage this important medical condition," said Greg Brown, ImpediMedâEUR(TM)s CEO. "ImpediMedâEUR(TM)s L-Dex family of devices has the potential to aid in this critical role in the preoperative assessment and management of lymphedema in female breast cancer patients".ImpediMedâEUR(TM)s technology was developed by The Queensland University of Technology and The University of Queensland. The company was formed in late 1999 by the University of Queensland in order to commercialize this technology.